Osteopenia and osteoporosis are metabolic conditions characterized by an imbalance between osteoclast relative to osteoblast activity. This metabolic balance in bone remodeling can be caused by either a deficiency in osteoblast activity (bone formation) or excessive osteoclast activity (bone resorption), leading to compromised bone architecture and increased risk of fracture. Epidemiological data suggest that intake of soy isoflavones confers a significant protective effect against the development of osteoporotic fracture in Asian populations. There are considerable regional differences in soy protein and isoflavone consumption, with Asian populations consuming an estimated 25-50 mg of isoflavone aglycone equivalents daily, with 10% of the population consuming more than 100 mg isoflavones daily. The relationship between isoflavone intake and bone loss is more robust in postmenopausal women, suggesting that isoflavone intake restores the metabolic balance of bone formation and resorption disrupted by menopausal ovarian hormone loss. In the United States and Europe soy consumption is only 5-10% of that in Asian countries, this justifies the search for isoflavone-based supplements, medical foods and drugs which can improve bone health, especially in postmenopausal women.
SOY ISOFLAVONES IN BONE HEALTH AND FUNCTION
BITTO, ALESSANDRA;SQUADRITO, Francesco
In corso di stampa
Abstract
Osteopenia and osteoporosis are metabolic conditions characterized by an imbalance between osteoclast relative to osteoblast activity. This metabolic balance in bone remodeling can be caused by either a deficiency in osteoblast activity (bone formation) or excessive osteoclast activity (bone resorption), leading to compromised bone architecture and increased risk of fracture. Epidemiological data suggest that intake of soy isoflavones confers a significant protective effect against the development of osteoporotic fracture in Asian populations. There are considerable regional differences in soy protein and isoflavone consumption, with Asian populations consuming an estimated 25-50 mg of isoflavone aglycone equivalents daily, with 10% of the population consuming more than 100 mg isoflavones daily. The relationship between isoflavone intake and bone loss is more robust in postmenopausal women, suggesting that isoflavone intake restores the metabolic balance of bone formation and resorption disrupted by menopausal ovarian hormone loss. In the United States and Europe soy consumption is only 5-10% of that in Asian countries, this justifies the search for isoflavone-based supplements, medical foods and drugs which can improve bone health, especially in postmenopausal women.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.